The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
BUSINESS Taiho Bags Label Update for Lonsurf Combo Use with Bevacizumab
March 29, 2024
-
REGULATORY Label Revision Ordered for CAR-T Therapies to Add New Precaution
March 29, 2024
-
REGULATORY Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
March 29, 2024
-
REGULATORY Japan Diet Passes FY2024 Budget, Record Social Security Spending
March 29, 2024
-
BUSINESS BIKEN Files Nasal Flu Vaccine in Japan
March 29, 2024
-
BUSINESS Padcev/Keytruda Accepted for Chinese Review for 1st Line Bladder Cancer Use
March 29, 2024
-
BUSINESS Sumitomo-Sponsored Trial for Parkinson’s Cell Therapy to Commence in US
March 29, 2024
-
BUSINESS Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
March 29, 2024
-
REGULATORY MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
-
BUSINESS Fuso Says Toray Jacked Up Damage Claim in Remitch Patent Suit
March 28, 2024
-
REGULATORY Japan’s HIV, AIDS Cases Rebound in 2023 after COVID
March 28, 2024
-
BUSINESS Sosei Group to Be Renamed “Nxera Pharma” from April
March 28, 2024
-
REGULATORY Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
March 28, 2024
-
BUSINESS Abilify Maintena Gets EU Nod as 1st 2-Month Injectable for Schizophrenia
March 28, 2024
-
BUSINESS AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
-
REGULATORY Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
-
BUSINESS Incyte Appoints Eiji Ueda as Japan Chief
March 27, 2024
-
REGULATORY PMDA Chief Fujiwara to Remain Skipper for Another Term
March 27, 2024
-
BUSINESS SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
-
BUSINESS One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…